Influenza and other respiratory virus infections in solid organ transplant recipients

Clinical Microbiology and Infection

Volumn 20, Issue s7, 2014, Pages 102-108

  Manuel, O ^a   Lopez Medrano F ^b   Kaiser, L ^c   Welte, T ^d   Carratala J ^e,f   Cordero, E ^g   Hirsch, H H ^h  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Universidad Complutense   (Spain)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antiviral therapy; Chronic allograft dysfunction; Influenza; Respiratory syncytial virus; Vaccination

Indexed keywords

ANTIVIRUS AGENT; RIBAVIRIN; IMMUNOSUPPRESSIVE AGENT;

ADENOVIRIDAE; ANTIVIRAL THERAPY; COMMUNITY ACQUIRED RESPIRATORY VIRUS; CORONAVIRUS; GRAFT RECIPIENT; HUMAN; HUMAN METAPNEUMOVIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFECTION PREVENTION; INFLUENZA; INFLUENZA VIRUS; MORBIDITY; MORTALITY; NUCLEIC ACID AMPLIFICATION; ORGAN TRANSPLANTATION; PARAINFLUENZA VIRUS; RESPIRATORY TRACT INFECTION; RESPIRATORY VIRUS; REVIEW; RHINOVIRUS; SOLID ORGAN TRANSPLANTATION; VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; OPPORTUNISTIC INFECTIONS; PATHOLOGY; RESPIRATORY TRACT INFECTIONS; VIROLOGY; VIRUS DISEASES;

HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION; RESPIRATORY TRACT INFECTIONS; TRANSPLANT RECIPIENTS; VIRUS DISEASES;

EID: 84908217711     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12595     Document Type: Review

References (59)

1. Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther 2007; 12(4 Pt B): 627-638.
2. Ison MG. Influenza, including the novel H1N1, in organ transplant patients. Curr Opin Infect Dis 2010; 23: 365-373.
3. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 2011; 11: 1071-1078.
4. Manuel O, Estabrook M, AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant 2013; 13(suppl 4): 212-219.
5. Cordero E, Perez-Romero P, Moreno A et al. Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clin Microbiol Infect 2012; 18: 67-73.
6. Kumar D, Michaels MG, Morris MI et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 2010; 10: 521-526.
7. Manuel O, Pascual M, Hoschler K et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis 2011; 52: 248-256.
8. Siegrist CA, Ambrosioni J, Bel M et al. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir Ther 2012; 17: 893-903.
9. Bridevaux PO, Aubert JD, Soccal PM et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax 2014; 69: 32-38.
10. Lopez-Medrano F, Cordero E, Gavalda J et al. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI). Enferm Infecc Microbiol Clin 2013; 31: 526.e1-526.e20.
11. Low CY, Kee T, Chan KP et al. Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore. Transplantation 2010; 90: 1016-1021.
12. Ng BJ, Glanville AR, Snell G et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant 2011; 11: 568-574.
13. Vilchez R, McCurry K, Dauber J et al. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation 2002; 73: 1075-1078.
14. Vilchez RA, McCurry K, Dauber J et al. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant 2002; 2: 287-291.
15. Lopez-Medrano F, Aguado JM, Lizasoain M et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation 2007; 84: 851-856.
16. Khanna N, Widmer AF, Decker M et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46: 402-412.
17. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56: 258-266.
18. Smud A, Nagel CB, Madsen E et al. Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study. Transplantation 2010; 90: 1458-1462.
19. Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001; 119: 1277-1280.
20. Uckay I, Gasche-Soccal PM, Kaiser L et al. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy. J Heart Lung Transplant 2010; 29: 299-305.
21. Gottlieb J, Schulz TF, Welte T et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009; 87: 1530-1537.
22. Kumar D, Husain S, Chen MH et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010; 89: 1028-1033.
23. Ariza-Heredia EJ, Fishman JE, Cleary T, Smith L, Razonable RR, Abbo L. Clinical and radiological features of respiratory syncytial virus in solid organ transplant recipients: a single-center experience. Transpl Infect Dis 2012; 14: 64-71.
24. Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant 2003; 3: 116-120.
25. Kaiser L, Aubert JD, Pache JC et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 2006; 174: 1392-1399.
26. Babakir-Mina M, Ciccozzi M, Perno CF, Ciotti M. The human polyomaviruses KI and WU: virological background and clinical implications. APMIS 2013; 121: 746-754.
27. Buller RS. Molecular detection of respiratory viruses. Clin Lab Med 2013; 33: 439-460.
28. Khanna N, Steffen I, Studt JD et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11: 100-105.
29. Kumar D, Blumberg EA, Danziger-Isakov L et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant 2011; 11: 2020-2030.
30. Cordero E, Aydillo TA, Perez-Ordonez A et al. Deficient long-term response to pandemic vaccine results in an insufficient antibody response to seasonal influenza vaccination in solid organ transplant recipients. Transplantation 2012; 93: 847-854.
31. Schuurmans MM, Tini GM, Dalar L, Fretz G, Benden C, Boehler A. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant 2011; 30: 685-690.
32. Perez-Romero P, Aydillo TA, Perez-Ordonez A et al. Reduced incidence of pneumonia in influenza-vaccinated solid organ transplant recipients with influenza disease. Clin Microbiol Infect 2012; 18: E533-E540.
33. Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol 2011; 6: 1192-1197.
34. Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS ONE 2013; 8: e56974.
35. Cordero E, Perez-Ordonez A, Aydillo TA et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. Am J Transplant 2011; 11: 2205-2213.
36. Orcurto A, Pascual M, Hoschler K, Aubert V, Meylan P, Manuel O. Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients. Transplantation 2012; 94: 630-636.
37. Sanchez-Fructuoso AI, Prats D, Naranjo P et al. Influenza virus immunization effectivity in kidney transplant patients subjected to two different triple-drug therapy immunosuppression protocols: mycophenolate versus azathioprine. Transplantation 2000; 69: 436-439.
38. Baluch A, Humar A, Eurich D et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant 2013; 13: 1026-1033.
39. McElhaney JE, Beran J, Devaster JM et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13: 485-496.
40. Danziger-Isakov L, Kumar D, AST Infectious Diseases Community of Practice. Vaccination in solid organ transplantation. Am J Transplant 2013; 13(suppl 4): 311-317.
41. Katerinis I, Hadaya K, Duquesnoy R et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant 2011; 11: 1727-1733.
42. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124: 1694-1701.
43. South East Asia Infectious Disease Clinical Research N. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ 2013; 346: f3039.
44. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol 2011 Dec; 1: 563-573.
45. Chen LF, Dailey NJ, Rao AK et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 2011; 203: 838-846.
46. Molinos-Quintana A, Perez-de Soto C, Gomez-Rosa M, Perez-Simon JA, Perez-Hurtado JM. Intravenous ribavirin for respiratory syncytial viral infections in pediatric hematopoietic SCT recipients. Bone Marrow Transplant 2013; 48: 265-268.
47. Glanville AR, Scott AI, Morton JM et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24: 2114-2119.
48. Keck M, Mindru C, Kalil AC, Mercer DF, Florescu DF. Respiratory syncytial virus lower respiratory tract infection in a pediatric liver transplant recipient treated with oral ribavirin. Pediatr Transplant 2012; 16: E348-E351.
49. Mori T, Nakamura Y, Kato J et al. Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2011; 93: 132-134.
50. Lehners N, Geis S, Eisenbach C, Neben K, Schnitzler P. Changes in severity of influenza A(H1N1)pdm09 infection from pandemic to first postpandemic season, Germany. Emerg Infect Dis 2013; 19: 748-755.
51. Fuehner T, Dierich M, Duesberg C et al. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections. Antivir Ther 2011; 16: 733-740.
52. Shima T, Yoshimoto G, Nonami A et al. Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient. Int J Hematol 2008; 88: 336-340.
53. Stankova J, Carret AS, Moore D et al. Long-term therapy with aerosolized ribavirin for parainfluenza 3 virus respiratory tract infection in an infant with severe combined immunodeficiency. Pediatr Transplant 2007; 11: 209-213.
54. Kalimuddin S, Sessions OM, Hou Y et al. Successful clearance of human parainfluenza virus type 2 viraemia with intravenous ribavirin and immunoglobulin in a patient with acute myocarditis. J Clin Virol 2013; 56: 37-40.
55. Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother 2008; 62: 437-441.
56. Raza K, Ismailjee SB, Crespo M et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant 2007; 26: 862-864.
57. Bonney D, Razali H, Turner A, Will A. Successful treatment of human metapneumovirus pneumonia using combination therapy with intravenous ribavirin and immune globulin. Br J Haematol 2009; 145: 667-669.
58. Shachor-Meyouhas Y, Ben-Barak A, Kassis I. Treatment with oral ribavirin and IVIG of severe human metapneumovirus pneumonia (HMPV) in immune compromised child. Pediatr Blood Cancer 2011; 57: 350-351.
59. Widmer N, Meylan P, Ivanyuk A, Aouri M, Decosterd LA, Buclin T. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet 2010; 49: 741-765.